Stem cells from umbilical cord against cancer
The stem cells regenerate the blood formation and reconstruct the immune system. On the umbilical cord there concentrate a high number of this type of cells.
In 2015 227.076 new cases of cancer are foreseen, according to the report of the Spanish Society of Medical Oncology (SEOM). The medical advances have demonstrated that the new therapies based on transplants of cells umbilical cord mother are an effective treatment against the cancer. If at the moment of the childbearing it is extracted and survives in private banks *, in case of illness the person will have them during all its life.
According to the experts, the probability of needing the stem cells increases on having done the age of the person and in children this probability is located approximately in 1:2000, and up to 70 years the risk increases to 1:7.
If the cells mother are transplanted to certain patients whose bone marrow sick finds, promising therapeutic successes can be obtained.
Efficacy of the blood transplant of umbilical cord in leukemia and neuroblastoma
Secuvita, the only company of securing and criopreservación of cells mother of the blood of the umbilical cord (SCU) in Spain with proper bank in Germany, Vita 34, is provided with several cases of success that demonstrate the efficacy of the transplant of cells mother of umbilical cord proper (transplant autólogo, in that the donor is the proper recipient) to treat the leukemia or the cancer of the nervous system. Cells umbilical cord blood mother preserved in Vita 34, the most common cancer was used for the first time eight years ago, in a leukemia treatment, in children. Twenty-four months after the treatment, the patient was free of cells leucémicas, experiencing a finished reference of the illness that is supported 9 years later.
At present, the girl is 12 years old and has not presented any relapsing symptom.
This girl, with 3 years was suffering leukemia linfoblástica sharp. After the first treatment with chemotherapy a rapid reference of the illness experimented, but ten months later the cancer reappeared extended to the bones of the column, what was revealing a type of leukemia especially aggressive. It was then when there administered mieloablativa chemotherapy and radiotherapy followed by a transplant of stem cells of her own umbilical cord, preserved in Vita 34, previous analysis to guarantee that it was free of carcinogenic cells.
Four months, after receiving the transplant, the patient was presenting an inventory plaquetario normally and he did not suffer any complication. This transplant autólogo of umbilical cord cells in the treatment of the infantile leukemia was the first case of success that demonstrated the viability and efficacy of the application of this skill like therapy for the pediatric leukemia.Also carcinogenic cells will not be in the blood of the umbilical cord of the patient, a find known until now.
Another case of success is the transplant autólogo of blood of umbilical cord of a 4-year-old girl to which a neuroblastoma was diagnosed in stadium 4, a type of cancer of the nervous system. After the first medical diagnosis with minimal possibilities of survival for the aggressiveness of the treatment of chemotherapy and radiotherapy, there was chosen to realize a transplant of cells mother of her own umbilical cord – preserved in Vita 34-, without rejection risk, to reconstruct its immune system after the treatment of the cancer by means of an intravenous infusion. One week later it had improved and at the age of three weeks it was leaving the hospital. After the transplant, the cells mother migrated up to the bone marrow, where they multiplied and began generating white globules, red globules and thrombocytes, initiating this way the regeneration of its blood system.
The radiation and the chemotherapy eliminate completely the tumor cells, without distinguishing between the cancerous ones and the healthy ones, that is to say, it destroys also the blood system of the patient; for it, it is necessary to mend the above mentioned system with cells mother.
The transplant of stem cells is one of the skills for it, since it allows the patients to be able to receive much raised doses of chemotherapy or of radiotherapy. The transplant of cells mother is done at a later stage to recover the lost healthy cells.
Secuvita: the only company in Spain with proper bank and its “Initiative Brothers”
Secuvita, biotechnological company dedicated to the securing and crioconservación of cells mother of umbilical cord (SCU), is the only one in Spain with proper bank in Germany, Vita 34, that there realizes one of the two familiar transplants with cells blood mother of drawstring preserved in private banks. Vita 34 preserves more than 20 % of the blood units of the whole Europe, 1 of every 5 blood units of umbilical cord, and accumulates the biggest experience in transplants: 28 transplants, which suppose a guarantee of the rigor of the conservation offered to the Spanish parents.
Of 28 transplants, 7 have been used for treatments against the cancer, two cases transplant autólogo and five alogénico, that is to say, the cells mother come from another individual who turns out to be compatible, related or not with the recipient, which if it it is usually talks each other of a brother.
The transplant alogénico related is helping to treat illnesses, especially in children. For this reason, Secuvita created “Initiative Brothers”, offering the free cells storage mothers for families with sick children without cost for five years. There are different the cases in which umbilical cord blood has been used for brothers, like a family with a five-year-old son with anemia aplásica, other with leukemia (ALL, leukemia linfocítica sharp), and a ten-year-old girl and a fourteen-year-old boy with beta – talasemia.
SECUVITA and VITA 34 work under quality regulation GMP (Good Manufacturing Practices), the most demanding, and it is registered in the FDA (American Agency of the Medicine) so that the blood of the baby is certified like medicine, so that the blood preserved in VITA 34 has the consideration of Completed Pharmaceutical Product and it is accepted for transplant by the international medical community.